Abraxis BioScience, Inc. Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycin’s Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles. Results from the pre-clinical study demonstrated that nab-rapamycin was well-tolerated, showed linear pharmacokinetics, and was highly effective against a number of tumor models in vivo. (Abstract #4719; Nanoparticle Albumin-bound (nab) Rapamycin as an Anticancer Agent).
MORE ON THIS TOPIC